500124:BOM
Dr Reddy's Laboratories Ltd
₹1.220,75
arrow_upward
+0,55%(+6,65) 1G
15 Eki, 15:30:00 GMT+5:30 · INR
search
Tüm semboller
| Sembol | Fiyat | Değişiklik | Değişiklik % |
|---|
insights_auto500124 ile ilgili en önemli analizler oluşturuluyor...
Açık
₹1.214,10
Yüksek
₹1.234,10
Düşük
₹1.207,85
Piy. değ.
1,02 Tn
Ort. hacim
86,23 B
İşlem Hacmi
112,66 B
Kâr payı
%0,66
Üç aylık temettü
₹2,00
Temettüsüz işlem tarihi
10 Tem 2026
F/K oranı
31,57
52 haftalık en yüksek
₹1.414,40
52 haftalık en düşük
₹1.080,05
HBK
₹38,67
Tedavüldeki hisse senedi sayısı
166,06 Mn
Çalışan sayısı
28 B
Açık
₹1.214,10
Yüksek
₹1.234,10
Düşük
₹1.207,85
Piy. değ.
1,02 Tn
Ort. hacim
86,23 B
İşlem Hacmi
112,66 B
Kâr payı
%0,66
Üç aylık temettü
₹2,00
Temettüsüz işlem tarihi
10 Tem 2026
F/K oranı
31,57
52 haftalık en yüksek
₹1.414,40
52 haftalık en düşük
₹1.080,05
HBK
₹38,67
Tedavüldeki hisse senedi sayısı
166,06 Mn
Çalışan sayısı
28 B
Haberler
Web kaynaklarından ve haber iş ortaklarından
MarketBeat
·
18 saat önce
Dr. Reddy's Laboratories (NYSE:RDY) Shares Cross Above Two Hundred Day Moving Average - Time to Sell?
TipRanks
·
1 gün önce
Dr. Reddy’s Receives USFDA Form 483 After Pre-Approval Inspection at Visakhapatnam Plant
www.marketscreener.com
·
3 gün önce
Dr. Reddy's Laboratories Shares Rise After BNP Paribas Upgrade
Profil
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
Dr Reddy's Laboratories Ltd hakkında
CEOErez Israeli
Çalışan Sayısı27,5 B
Kuruluş Tarihi1984
Genel MerkezHaydarabad, Andra Pradeş, Hindistan
Sektör-
Web Sitesidrreddys.com